FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
Category: #health  By Mateen Dalal  Date: 2019-06-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment

NuCana is on its way to open a Global Phase III study of Acelarin in combination with cisplatin for patients who are suffering from the disease in 2019

NuCana plc recently announced that it has received Orphan Drug Designation for Acelarin, an investigational drug, from the U.S. Food and Drug Administration (FDA) to treat Biliary Tract Cancer. Acelarin is a ProTide transformation of gemcitabine and a new chemical entity that NuCana has produced.

Founder and Chief Executive Officer, Hugh Griffith said that there are considerable unmet requirements for patients suffering from this type of cancer.  The company performed an Phase 1b study on the combination of Acelarin and cisplatin that showed nearly double response rate, as compared with the standard of care ( gemcitabine plus cisplatin), he mentioned.

Griffith stated that many patients achieved a significant reduction in the volume of their tumor along with further shrinkage of the tumor with time. The company believes that Acelarin is a potential example of a notable advancement in biliary tract cancer and they are on their way to open their Global Phase III study with the combination of cisplatin for patients who are suffering from the disease in 2019, Griffith added.

For the record, Orphan Drug Designation is given to drugs by the FDA that are defined for prevention, diagnosis or treatment of rare diseases or conditions which are affecting less than 200,000 people in America. It provides benefits and incentives like prescription drug user fee waiver and tax credits for clinical trial cost.

For the uninitiated, NuCana plc is a clinical-stage biopharmaceutical company, which is focusing on enhancing treatment outcomes for patients suffering from cancer by applying the company’s ProTide Technology. It supposedly helps in transforming largely prescribed nucleoside analogs, chemotherapy agents into safer and more effective medicines.

Biliary tract cancer is reportedly a type of cancer that starts in the bile duct system connecting to liver, gallbladder and small intestine carrying digestive fluid through the liver.

 

Source Credit: https://www.globenewswire.com/news-release/2019/06/12/1868106/0/en/NuCana-Receives-Orphan-Drug-Designation-from-the-U-S-Food-and-Drug-Administration-for-Acelarin-for-the-Treatment-of-Biliary-Tract-Cancer.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...